BEST AVAILABLE COPY

TOWNSEND
and
TOWNSEND
and
CREW
LLP

Denver, Colorado
Tel 303 571-4000

Palo Alto, California
Tel 650 326-2400

Seattle, Washington
Tel 206 467-9600

San Francisco

Two Embarcadero Center
Eighth Floor
San Francisco
California 94111-3834
Tel 415 576-0200
Fax 415 576-0300

August 14, 2003

VIA EXPRESS MAIL, WITH RETURN POSTCARD ENCLOSED
PCT International Application Processing Div.
USPTO International Division
Assistant Commissioner for Patents
Mail Stop PCT
P.O. Box 1450
Alexandria, VA 22313-1450

Re: International Application No. PCT/US03/02353
Applicants: CORIXA CORPORATION *et al.*
Inventors: Gaiger *et al.*
Filed: 22 January 2003
Express Mail Label No.: EV 332 017 306 US
Date of Mailing: 14 August 2003
Our File No.: 14058-14402P

Dear Officer:

Enclosed are the Chapter II Demand with ten (10) substitute pages 15, 20, 20a, 22, 161, 167, 167a, 169, 171, and 234 of the Specification, and fifteen (15) sheets of Formal Drawings (Figs. 1-8), submitted as Amendments under Article 34. The only changes were corrections to typographical errors and the insertions of SEQ ID:NOs. that do not include matter which go beyond the disclosure in the international application as filed.

It is hereby stated that "the information recorded on the computer readable form is identical to the written sequence listing" and does not include matter which goes beyond the disclosure in the international application as filed.

Thank you for your attention to this matter.

Respectfully submitted,

Carol A. Fang

CAF:kji
Enclosures: Chapter II Demand
Substitute pages 15, 20, 20a, 22, 161, 167, 167a, 169, 171, and 234
Fifteen (15) sheets of Formal Drawings (Figs. 1-8)
One hundred twenty (120) pages of Sequence Listing
Diskette and Statement
Transmittal Letter
Postcard

60018168 v1

10 Rec'd PCT/ JUL 2004

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent, with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/ US

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty:
The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

For International Preliminary Examining Authority use only

Identification of IPEA	Date of receipt of DEMAND

Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION		Applicant's or agent's file reference 14058-14402P
International application No. PCT/US03/02353	International filing date (*day/month/year*) 22 January 2003 (22.01.03)	(Earliest) Priority date (*day/month/year*) 22 January 2002 (22.01.02)

Title of invention

COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES

Box No. II APPLICANT(S)

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)	Telephone No.: 206.754.5711
CORIXA CORPORATION 1124 Columbia Street, Suite 200 Seattle, Washington 98104 United States of America	Facsimile No.: 206.754.5994
	Teleprinter No.:
	Applicant's registration No. with the Office

State (*that is, country*) of nationality:	State (*that is, country*) of residence:
US	US

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

GAIGER, Alexander
Doeblinger Hauptstrasse 62/14
A-1190 Vienna
Austria

State (*that is, country*) of nationality:	State (*that is, country*) of residence:
AT	AT

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

ALGATE, Paul, A.
580 Kalmia Place, NW
Issaquah, Washington 98027
United States of America

State (*that is, country*) of nationality:	State (*that is, country*) of residence:
GB	US

☒ Further applicants are indicated on a continuation sheet.

Sheet No. 2

International application No.
PCT/US03/02353

Continuation of Box No. II APPLICANT(S)

If none of the following sub-boxes is used, this sheet should not be included in the demand.

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

MANNION, Jane
8904 192nd Street, SW
Edmonds, Washington 98026
United States of America

State (*that is, country*) of nationality:	State (*that is, country*) of residence:
US	US

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

CLAPPER, Jonathan, David
2149 Dexter Avenue, North, #4
Seattle, Washington 98109
United States of America

State (*that is, country*) of nationality:	State (*that is, country*) of residence:
US	US

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

WANG, Aijun
3106 - 213th Place, SE
Issaquah, Washington 98029
United States of America

State (*that is, country*) of nationality:	State (*that is, country*) of residence:
CN	US

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

ORDONEZ, Nadia
2011 No. 154 Court
Seattle, Washington 98133
United States of America

State (*that is, country*) of nationality:	State (*that is, country*) of residence:
US	US

☒ Further applicants are indicated on a continuation sheet.

International application No.
PCT/US03/02353

Continuation of Box No. II APPLICANT(S)

If none of the following sub-boxes is used, this sheet should not be included in the demand.

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

CARTER, Lauren
7143 Beach Drive, SW
Seattle, Washington 98136
United States of America

State (*that is, country*) of nationality:	State (*that is, country*) of residence:
US	US

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

MCNEILL, Patricia, Dianne
1333 South - 290th Place
Federal Way, Washington 98003
United States of America

State (*that is, country*) of nationality:	State (*that is, country*) of residence:
US	US

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

State (*that is, country*) of nationality:	State (*that is, country*) of residence:

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

State (*that is, country*) of nationality:	State (*that is, country*) of residence:

☐ Further applicants are indicated on a continuation sheet.

International application No.
PCT/US03/02353

Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The following person is ☒ agent ☐ common representative

and ☒ has been appointed earlier and represents the applicant(s) also for international preliminary examination.

☐ is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.

☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.*)

Carol A. Fang
TOWNSEND AND TOWNSEND AND CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
United States of America

Telephone No.:
415-576-0200

Facsimile No.:
415-576-0300

Teleprinter No.:

Agent's registration No. with the Office
48,631

☐ **Address for correspondence:** Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION

Statement concerning amendments:*

1. The applicant wishes the international preliminary examination **to start on the basis of**:

☒ the international application as originally filed

the description
☐ as originally filed
☒ as amended under Article 34

the claims
☒ as originally filed
☐ as amended under Article 19 (together with any accompanying statement)
☐ as amended under Article 34

the drawings
☐ as originally filed
☒ as amended under Article 34

2. ☐ The applicant wishes any amendment to the claims under Article 19 to be considered as reversed.

3. ☐ The applicant wishes the start of the international preliminary examination **to be postponed** until the expiration of 20 months from the priority date unless the International Preliminary Examining Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). (*This check-box may be marked only where the time limit under Article 19 has not yet expired.*)

* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Language for the purposes of international preliminary examination: ENGLISH

☒ which is the language in which the international application was filed.
☐ which is the language of a translation furnished for the purposes of international search.
☐ which is the language of publication of the international application.
☐ which is the language of the translation (to be) furnished for the purposes of international preliminary examination.

Box No. V ELECTION OF STATES

The applicant hereby **elects all eligible States** (*that is, all States which have been designated and which are bound by Chapter II of the PCT*)

excluding the following States which the applicant wishes not to elect:

Sheet No. 5

International application No.
PCT/US03/02353

Box No. VI CHECK LIST

The demand is accompanied by the following elements, in the language referred to in Box No. IV, for the purposes of international preliminary examination:

				For International Preliminary Examining Authority use only	
				received	not received
1.	translation of international application	:	sheets	☐	☐
2.	amendments under Article 34	:	25 sheets	☐	☐
3.	copy (or, where required, translation) of amendments under Article 19	:	sheets	☐	☐
4.	copy (or, where required, translation) of statement under Article 19	:	sheets	☐	☐
5.	letter	:	1 sheet	☐	☐
6.	other (*specify*)	:	sheets	☐	☐

The demand is also accompanied by the item (s) marked below:

1. ☒ fee calculation sheet
2. ☐ original separate signed power of attorney
3. ☐ original general power of attorney;
4. ☐ copy of general power of attorney; reference number, if any:
5. ☐ statement explaining lack of signature
6. ☒ sequence listing in computer readable form
7. ☐ tables in computer readable form related to sequence listings
8. ☒ other (*specify*) Transmittal Letter, Article 34 Amendment with ten (10) substitute pages 15, 20, 20a, 22, 161, 167, 167a, 169, 171, and 234; fifteen (15) sheets of Formal Drawings (Figs. 1-8); Statement; Sequence Listing (120 pages), and Diskette; and Postcard

Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).

X _____

Carol A. Fang
TOWNSEND AND TOWNSEND AND CREW LLP
USPTO Reg. No. 48,631
Applicants' Agent

For International Preliminary Examining Authority use only

1. Date of actual receipt of DEMAND:
2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):
3. ☐ The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply. ☐ The applicant has been informed accordingly.
4. ☐ The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5.
5. ☐ Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.

For International Bureau use only

Demand received from IPEA on:

CHAPTER II

PCT

FEE CALCULATION SHEET

Annex to the Demand

For International Preliminary Examining Authority use only

International application No.	PCT/US03/02353
Applicant's or agent's file reference	14058-14402P

Date stamp of the IPEA

Applicant

CORIXA CORPORATION *et al.*

CALCULATION OF PRESCRIBED FEES

1. Preliminary examination fee	$490.00	P
2. Handling fee (*Applicants from certain States are entitled to a reduction of 75% of the handling fee. Where the applicant is (or all applicants are) so entitled, the amount to be entered at H is 25% of the handling fee.*)	$172.00	H
3. Total of prescribed fees Add the amounts entered at P and H and enter total in the TOTAL box	$662.00	TOTAL

MODE OF PAYMENT

- ☒ authorization to charge deposit account with the IPEA (see below)
- ☐ cash
- ☐ cheque
- ☐ revenue stamps
- ☐ postal money order
- ☐ coupons
- ☐ bank draft
- ☐ other (*specify*):

AUTHORIZATION TO CHARGE (OR CREDIT) DEPOSIT ACCOUNT

(*This mode of payment may not be available at all IPEAs*)

The IPEA/ US

☒ is hereby authorized to charge the total fees indicated above to my deposit account.

☒ (*this check-box may be marked only if the conditions for deposit accounts of the IPEA so permit*) is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account.

20-1430	14 August 2003	Carol A. Fang
Deposit Account Number	Date (*day/month/year*)	Signature

See Notes to the fee calculation sheet

56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121 herein.

[38] In still other embodiments, the preferred peptides and polypeptides of the present invention comprise a sequence of at least about 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, or 400 or more contiguous amino acids as disclosed in any one or more of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121 herein.

[39] The polypeptides of the invention typically will comprise at least a first contiguous amino acid sequence according to any one of the peptides encoded by any one of the above polynucleotides or disclosed in any one of SEQ ID NOs:10,471-10,474; SEQ ID NO:10,481; SEQ ID NOs:10,599 – 10,819; SEQ ID NOs:10,820-10,842; SEQ ID NOs:10,849-10,908; and SEQ ID NOs:10,909-10,968 of co-pending application USSN 10/057,475, but may also, optionally comprise at least a second, at least a third, or even at least a fourth or greater contiguous amino acid sequence according to any one of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. A single polypeptide may contain only a single coding region, or alternatively, a single polypeptide may comprise a plurality of identical or distinctly different contiguous amino acid sequences in accordance with any one of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. In fact, the polypeptide may comprise a plurality of the same contiguous amino acid sequences, or they may comprise one or more different contiguous amino acid sequences of any of the peptides encoded by any one

[50] **FIG. 3** illustrates a schematic outline of the general protocol for in vitro whole gene $CD4^+$ T cell priming procedure used to generate antigen-specific lines and to identify clones of interest.

[51] **FIG. 4** illustrates the panel of probes used to identify cDNAs that are overexpressed in lymphoma cells.

[52] **FIG. 5** lists the antigens that have similar tissue expression profiles as the known therapeutics, CD20 and CD52.

[53] **FIG. 6** illustrates the results of the TMpred report for Ly1484 long (SEQ ID NO:120) and Ly1484 short (SEQ ID NO:121).

[54] **FIG. 7** illustrates the results of the TSITES analysis of Ly1484 long (SEQ ID NO:120).

[55] **FIG. 8** illustrates the results of the TSITES analysis of Ly1484 short (SEQ ID NO:121).

[56] **SEQ ID NO:1** is a full-length cDNA for Ly1728P.

[57] **SEQ ID NO:2** is a full-length protein sequence for Ly1728P.

[58] **SEQ ID NO:3** is a full-length cDNA sequence of Ly1732P.

[59] **SEQ ID NO:4** is a full-length protein of Ly1732P.

[60] **SEQ ID NO:5** is a full length cDNA sequence of Ly1888P.

[61] **SEQ ID NO:6** is a full length protein sequence of Ly1888P.

[62] **SEQ ID NO:7** is a full length cDNA sequence of Ly1452_His-tag-fusion.

[63] **SEQ ID NO:8** is a full length protein sequence of Ly1452_His-tag-fusion.

[64] **SEQ ID NO:9** is a full length cDNA sequence of Ly1452P, splice variant 1.

[65] **SEQ ID NO:10** is a full length protein sequence of Ly1452P, splice variant 1.

[66] **SEQ ID NO:11** is a full length cDNA sequence of Ly1452P, splice variant 2.

[67] **SEQ ID NO:12** is a full length protein sequence of Ly1452P, splice variant 2.

[68] **SEQ ID NO:13** is a partial cDNA sequence of Ly1462P.

[69] **SEQ ID NO:14** is a full length cDNA sequence of Ly1462P.

[70] **SEQ ID NO:15** is a full length protein sequence of Ly1462P.

[71] **SEQ ID NO:16** is a partial cDNA sequence of Ly1484P.

[72] **SEQ ID NO:17** is a full length cDNA sequence of Ly1484P.

[73] **SEQ ID NO:18** is a full length protein sequence of Ly1484P.

[74] **SEQ ID NO:19** is a partial cDNA sequence of Ly1486P.

[75] **SEQ ID NO:20** is a full length cDNA sequence of Ly1486P.

[76] **SEQ ID NO:21** is a full length protein sequence of Ly1486P.

[77] **SEQ ID NO:22** is a partial cDNA sequence of Ly1677P.

[78] **SEQ ID NO:23** is a partial cDNA sequence of Ly1682P.

[113] **SEQ ID NO:58** is a full-length protein sequence of CD138.

[114] **SEQ ID NO:59** is a partial cDNA sequence of CD22.

[115] **SEQ ID NO:60** is a full-length cDNA sequence of CD22.

[116] **SEQ ID NO:61** is a full-length protein sequence of CD22.

[117] **SEQ ID NO:62** is a partial cDNA sequence of CD79beta.

[118] **SEQ ID NO:63** is a partial protein sequence of CD79beta.

[119] **SEQ ID NO:64** is a partial cDNA sequence of CD79beta.

[120] **SEQ ID NO:65** is a full-length cDNA sequence of CD79beta.

[121] **SEQ ID NO:66** is a full-length protein sequence of CD79beta.

[122] **SEQ ID NO:67** is a partial cDNA sequence of Ly1450P.

[123] **SEQ ID NO:68** is a partial cDNA sequence of Ly1450P.

[124] **SEQ ID NO:69** is a partial cDNA sequence of Ly1451P.

[125] **SEQ ID NO:70** is a partial cDNA sequence of Ly1451P.

[126] **SEQ ID NO:71** is a partial protein sequence of Ly1451P.

[127] **SEQ ID NO:72** is a partial cDNA sequence of Ly1454P.

[128] **SEQ ID NO:73** is a full-length cDNA sequence of Ly1454P.

[129] **SEQ ID NO:74** is a full-length protein sequence of Ly1454P.

[130] **SEQ ID NO:75** is a partial cDNA sequence of Ly1485P.

[131] **SEQ ID NO:76** is a partial protein sequence of Ly1485P.

[132] **SEQ ID NO:77** is a partial cDNA sequence of Ly1485P.

[133] **SEQ ID NO:78** is a partial cDNA sequence of Ly1500P.

[134] **SEQ ID NO:79** is a full-length cDNA sequence of Ly1500P, splice variant 1.

[135] **SEQ ID NO:80** is a full-length protein sequence of Ly1500P, splice variant 1.

[136] **SEQ ID NO:81** is a full-length cDNA sequence of Ly1500P, splice variant 2.

[137] **SEQ ID NO:82** is a full-length protein sequence of Ly1500P, splice variant 2.

[138] **SEQ ID NO:83** is a full-length cDNA sequence of Ly1500P, splice variant 3.

[139] **SEQ ID NO:84** is a full-length protein sequence of Ly1500P, splice variant 3.

[140] **SEQ ID NO:85** is a partial cDNA sequence of Ly1516P.

[141] **SEQ ID NO:86** is a full-length cDNA sequence of Ly1516P, splice variant 1.

[142] **SEQ ID NO:87** is a full-length protein sequence of Ly1516P, splice variant 1.

[143] **SEQ ID NO:88** is a partial cDNA sequence of Ly1516P, splice variant 2.

[144] **SEQ ID NO:89** is a partial cDNA sequence of Ly1516P, splice variant 3.

[145] **SEQ ID NO:90** is a partial cDNA sequence of Ly1678P.

[146] **SEQ ID NO:91** is a partial cDNA sequence of Ly1678P.

mRNA, and the reproducibility of the technology may be ensured by including duplicated control cDNA elements at different locations.

[620] Analysis of hematological malignancy subtracted clones by microarray analyses on a variety of microarray chips identified the sequences set forth in SEQ ID NO:1 through SEQ ID NO:664 of co-pending application USSN 09/796,692 as being at least two-fold overexpressed in hematological malignancies versus normal tissues.

5.3 EXAMPLE 3 – POLYNUCLEOTIDE AND POLYPEPTIDE COMPOSITIONS: BRIEF DESCRIPTION OF THE cDNA CLONES AND OPEN READING FRAMES IDENTIFIED BY SUBTRACTIVE HYBRIDIZATION AND MICROARRAY ANALYSIS

[621] Table 7 in co-pending application USSN 09/796,692 lists the sequences of the polynucleotides obtained during the analyses of the present invention. Shown are the 664 polynucleotide sequences, along with their clone name identifiers, as well as the serial number and filing date of the priority provisional patent application in which the clone was first identified. Also listed in Table 7 are the TCL-1 DNA and protein (SEQ ID NOS:665 and 666) and coronin 1A DNA and protein (SEQ ID NOS:667 and 668).

[622] Table 8 in co-pending application USSN 09/796,692 identifies the putative open reading frames obtained from analyses of the cDNA sequences obtained in SEQ ID NO:1-SEQ ID NO:664 in the co-pending application. Shown are the sequence identifiers, the clone name and translation frame, and the start and stop nucleotides in the corresponding DNA sequence used to generate the polypeptide sequence of the open reading frame (SEQ ID NOS:669-2532).

[623] Table 9 in co-pending application USSN 09/796,692 identifies an additional set of particular hematological malignancy-related cDNA sequences that were obtained using the subtractive library and microarray methods as described above. These sequences, designated SEQ ID NO:2533-SEQ ID NO:9597 in the co-pending application USSN 09/796,692, are shown in the Table along with the original clone name, and the serial number and filing date of the priority provisional application in which the clone was first described.

5.4 EXAMPLE 4 – ADDITIONAL ANALYSIS OF cDNA CLONES AND ORFS IDENTIFIED BY SUBTRACTIVE HYBRIDIZATION AND MICROARRAY ANALYSIS

[624] This example describes microarray analysis of leukemia tumor- and tissue-specific cDNAs.

[660] For Ly1859P, amino acid residues 128-144, 293-311, 408-425, 435-454, 465-483, 516-533, 290-311; 435-456, and 507-528 of SEQ ID NO:107 were identified as putative transmembrane domains.

[661] For Ly1866P, amino acids 47-65 and 50-71 of SEQ ID NO:109 were identified as putative transmembrane domains.

[662] For Ly669S, amino acids 489-505, 13-29, 38-57, 73-89, 94-114, 252-268, 307-324, 329-346, 489-509, 4-25, and 486-507 of SEQ ID NO:114 were identified as putative transmembrane domains.

[663] For Ly672S, amino acids 11-27, 284-300, 325-341, 345-361, 407-423, 7-28, 102-118, 174-198, 283-299, 325-341, 347-383, 403-423, 431-454, 473-492, 11-32, 286-307, 322-343, 345-366, 404-425, 430-451, and 469-490 of SEQ ID NO:117 were identified as putative transmembrane domains.

[664] For Ly675S, amino acids 154-170, 187-203, 428-444, 518-534, 846-862, 81-97, 155-172, 235-251, 374-391, 428-444, 477-195, 520-542, 539-573, 694-714, 807-823, 843-862,50-71, 77-98, 145-166, 518-539, 802-823, and 845-866 of SEQ ID NO:119 were identified as putative transmembrane domains.

5.8 EXAMPLE 8 – REALTIME PCR ANALYSIS TO IDENTIFY ANTIGENS OVEREXPRESSED IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

[665] Overexpression of candidate antigens in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM)was confirmed by RealTime PCR.

[666] Real-time PCR evaluates the level of PCR product accumulation during amplification (*see, e.g.*, Gibson *et al.*, Genome Research 6:995-1001 (1996); Heid *et al.*, Genome Research 6:986-994 (1996)). RealTime PCR permits quantitative evaluation of mRNA levels in multiple samples. Briefly, mRNA is extracted from tumor and normal tissue and cDNA is prepared using standard techniques. Real-time PCR is performed, for example, using a Perkin Elmer/Applied Biosystems (Foster City, CA) 9700 Prism instrument. Matching primers are designed for genes of interest using, for example, the primer express program provided by Perkin Elmer/Applied Biosystems (Foster City, CA). Optimal concentrations of primers and probes are initially determined by those of ordinary skill in the art, and control (*e.g.*, β-actin) primers and probes are obtained commercially from, for example, Perkin

Elmer/Applied Biosystems (Foster City, CA). To quantitate the amount of specific RNA in a sample, a standard curve is generated using a plasmid containing the gene of

Ly1866P	yes	yes
Ly1867P	yes	no
Ly1868P	yes	no
Ly1886P	yes	no
Ly669S	yes	yes
Ly672S	yes	yes
Ly675S	yes	yes

[667] These sequences can conveniently be used to diagnose, treat, and prevent malignant diseases that overexpress these genes, including multiple myeloma, B-cell lymphomas, and B-CLL. For example, monoclonal antibodies, including humanized monoclonal antibodies can be used for diagnosis and therapy of disorders associated with expression of antigens overexpressed in hematological malignancies.

5.9 EXAMPLE 9 - SEQUENCE ANALYSES, EXPRESSION ANALYSES, AND STRUCTURE ANALYSES OF OTHER ANTIGENS WITH SIMILAR EXPRESSION PROFILES AS CD20 & CD52

Summary of Results

Antigen	Sequence Analysis
Ly1728P	FOAP-12 ("novel gene over-expressed in macrophages")
Ly1732P	B-cell maturation factor (BCM), tumor necrosis factor receptor superfamily, member 17. BCM bins to TALL-1, a member of the TNF family.
Ly1888P	anti-Fas-induced apoptosis protein (TOSO); experimentally shown to be expressed on the cell surface.
Ly 1452P	anti-Fas-induced apoptosis protein (TOSO); experimentally shown to be expressed on the cell surface.
Ly1462P	Human Epstein-Barr virus complement receptor type II
Ly1484P	KIAA1607 (cDNA sequence present in GenBank).
Ly1486P	Fc fragment of IgE, low affinity II receptor.
Ly1677P	novel
Ly1682P	novel
Ly1693P	Chemokine receptor CXCR4
Ly1697P	novel
Ly1715P	lectin-like NK cell receptor
Ly1727P	Splice variants of the hpim-2 gene (homologs of the mouse pim-2 oncogene). Predicted to be a serine threonine kinase with a role in cell proliferation.
Ly1905P	Splice variants of the hpim-2 gene (homologs of the mouse pim-2 oncogene). Predicted to be a serine threonine kinase with a role in cell proliferation.
Ly1885P	An apparent splice form of the cell cycle progression 8 protein: one of a family of proteins involved in restoration of cell cycle progression (by blocking arrest in G1 phase).
Ly663S	leukocyte surface antigen CD37

(template #1076101.8; SEQ ID NO:124 that contained all 240bp of Ly1451. This template consisted of sequences from 6 clones, of which 2 (33%) were derived from hematologic/immune tissue libraries. Template #1076101.8 was part of a bin containing 11 templates derived from a total of 104 clones, of which 12 (9%) were derived from hematologic/immune tissue libraries.

[669] This sequence (SEQ ID NO:124) was used to search further public databases but no additional sequences were obtained. However, these searches indicate this sequence is a human endogenous retroviral sequence (HERV) encoding polypeptides corresponding to portions of the integrase and envelope genes. A single ORF with an ATG translational start site is contained in the forward read of LS1076101.8

[670] The polypeptide encoded by this ORF (SEQ ID NO:124) is not predicted to have a transmembrane domain.

5.11 EXAMPLE 11 –EXPRESSION OF LY1452 LYMPHOMA ANTIGENS ENCODED BYA SPECIFIC GENE, LY1452, ASSOCIATED WITH B CELL LEUKEMIAS, LYMPHOMAS AND MULTIPLE MYELOMAS

[671] Recombinantly expressed Ly1452 antigens were constructed to allow for quick and easy purification of the protein.

[672] The open reading frame for Ly1452 was PCR amplified and subcloned into a modified pET28 vector with a His tag in-frame and recombinantly expressed in *E. coli* (His-Ly1452: SEQ ID NO:7 (nt), SEQ ID NO:8 (protein).

Ly1452P expression in E. coli

[673] The open reading frame of the LS coding region was PCR amplified with the following primers:

PDM-797 5' gtgtcacaatctacagtcaggcaggattctcc 3' Tin 64°C
(SEQ ID NO:122)
PDM-799 5' gttatgtagcggccgcttatcatgttgctgcagag 3' Tm 67°C
(SEQ ID NO:123)

[674] Using the following conditions:

10µl 10X Herculase buffer
1 µl 10mM dNTPs
2µl 10µM each oligo
83µl sterile water
1.0µl Herculase DNA polymerase (Stratagene, La Jolla, CA)
50 ηg DNA

atctccccagagctgtctggggccatggtggtgggggacgtgctctgtctggccactgttctgaccagcc
tggaaggcctctcaggaacctggagctcctcagccaacagcatcctccacatcgaccccaagacgggtgt
ggctgtggcccgggccgtgggatccgtgacggtttactatgaggtcgctgggcacctgaggacctacaag
gaggtggtggtcagcgtccctcagaggatcatggcccgtcacctccaccccatccagacaagcttccagg
aggctacagcctccaaagtgattgttgccgtgggagacagaagctctaacctgagaggcgagtgcacccc
cacccagagggaagtcatccaggccttgcacccagagaccctcatcagctgccagtcccagttcaagccg
gccgtctttgatttcccatctcaagatgtgttcaccgtggagccacagtttgacactgctctcggccagt
acttctgctcaatcacaatgcacaggctgacggacaagcagcggaagcacctgagcatgaagaagacagc
tctggtggtcagtgcctccctctccagcagccacttctccacagagcaggtgggggccgaggtgcccttc
agcccaggtctcttcgccgaccaggctgaaatccttttgagcaaccactacaccagttccgagatcaggg
tctttggtgccccggaggttctggagaacttggaggtgaaatccgggtccccggccgtgctggcattcgc
aaaggagaagtcttttgggtggcccagcttcatcacatacacggtcggcgtctcggaccccgcggctggc
agccaagggcctctgtccactaccctgaccttctccagccccgtgaccaaccaagccattgccatcccag
tgacagtggcttttgtgatggatcgccgtgggcccggtccttatggagccagcctcttccagcacttcct
ggattcctaccaggtcatgttcttcacgctcttcgccctgttggctgggacagcggtcatgatcatagcc
taccacactgtctgcacgccccgggatcttgctgtgcctgcagccctcacgcctcgagccagccctggac
acagcccccactatttcgctgcctcatcacccacatctcccaatgcattgcctcctgctcgcaaagccag
ccctccctcagggctgtggagcccagcctatgcctcccactaggccgcgtgaaggttcccggaggatggg
tctcagccgagcctcgtgcacccccaagatggaacatccctgctgcattcacactggaacaagcccctcc
agatgagtgccccggccccaggccagcttcactgccgtctcttcacacagagctgtagtttcggctctgc
ccattagctcatttttatgtaggagttttaaatgtgtgttttttttcctttcaagtcttacaaagctaagac
tttttggctcattcctttttgcatggttgtctagggtttctggacaatgtgctgttgcatttttatttttc
ctagccttgctaaaatctttcccttctcaagactttgagcagttagaagtgctctttagaagttgtctgt
gggtgatgttactgtagtggtctcagggaaaggattgtccagttactttaggggtttttggtggggttt
ttccccctgtgaaaacttactttgcccctagtctggctgctgctaggacttctgaggagcaatgggacat
gagtgtccctgtatctgcgccactgccgcaagggaagcctcaggaaccagcacctggaggccaggatagc
caagccctgggtgagcgagaggctggagaacacaggagctcacccagggctgctgcccaaccatgggcca
ctgtgaacagacttcagtcctctgtttttgtttcataagccgttgagacatctgatggacttggcttagg
ccctgctgggacatcccacgtgtgatccctttcactccatcaggacaccaggactgtccttaggaaaatg
tccttgagatggcagcaggagtcatattttctgtgtgtgtgtttcggaaagccgctgtgtcctgcctcag
cacaaagacccagtgtcatttgctcctcctgttcctgtgccactccagaacctcagcagatctgagccac
cgcctgccagtgtgagaggcggccactttcatggcagcttatcaggcgcagggccccagacagcttccca
gccggccctagagcccggcctgggccaatgatggagggcggccaccagcccagggcctgcccatccagaa
gggactccccagggcctgggggaggagacccttggaaaagtcctctcttcccagctcctgattctggatc
tgagattctcagatcacaggcccctgtgctccaggccgaggctgggccaccctcagggagatccagagac
tcatgcccatggccatccatgcgtggacgctgtgtggagagtccaggatgacgggatcccgcacaagctc
ccttcagtccttcagggctgggccatgtggttgatttttctaaagctggagaaaggaagaattgtgcctt
gcatattacttgagcttaaactgacaacctggatgtaaataggagcctttctactggtttatttaataaa
gttctatgtgatttttt

119>Ly675S, KIAA0906 protein, partial protein
FPAPAKAVVYVSDIQELYIRVVDKVEIGKTVKAYVRVLDLHKKPFLAKYFPFMDLKLRAASPIITLVALD
EALDNYTITFLIRGVAIGQTSLTASVTNKAGQRINSAPQQIEVFPPFRLMPRKVTLLIGATMQVTSEGGP
QPQSNILFSISNESVALVSAAGLVQGLAIGNGTVSGLVQAVDAETGKVVIISQDLVQVEVLLLRAVRIRA
PIMRMRTGTQMPIYVTGITNHQNPFSFGNAVPGLTFHWSVTKRDVLDLRGRHHEASIRLPSQYNFAMNVL
GRVKGRTGLRVVVKAVDPTSGQLYGLARELSDEIQVQVFEKLQLLNPEIEAEQILMSPNSYIKLQTNRDG
AASLSYRVLDGPEKVPVVHVDEKGFLASGSMIGTSTIEVIAQEPFGANQTIIVAVKVSPVSYLRVSMSPV
LHTQNKEALVAVPLGMTVTFTVHFHDNSGDVFHAHSSVLNFATNRDDFVQIGKGPTNNTCVVRTVSVGLT
LLRVWDAEHPGLSDFMPLPVLQAISPELSGAMVVGDVLCLATVLTSLEGLSGTWSSSANSILHIDPKTGV
AVARAVGSVTVYYEVAGHLRTYKEVVVSVPQRIMARHLHPIQTSFQEATASKVIVAVGDRSSNLRGECTP
TQREVIQALHPETLISCQSQFKPAVFDFPSQDVFTVEPQFDTALGQYFCSITMHRLTDKQRKHLSMKKTA
LVVSASLSSSHFSTEQVGAEVPFSPGLFADQAEILLSNHYTSSEIRVFGAPEVLENLEVKSGSPAVLAFA
KEKSFGWPSFITYTVGVSDPAAGSQGPLSTTLTFSSPVTNQAIAIPVTVAFVMDRRGPGPYGASLFQHFL
DSYQVMFFTLFALLAGTAVMIIAYHTVCTPRDLAVPAALTPRASPGHSPHYFAASSPTSPNALPPARKAS
PPSGLWSPAYASH

<210> 120
<211> 1270
<212> PRT
<213> Homo sapiens

<400> 120
Arg Asp Phe Gln Ser Glu Val Leu Leu Ser Ala Met Glu Leu Phe His
1 5 10 15
Met Thr Ser Gly Gly Asp Ala Ala Met Phe Arg Asp Gly Lys Glu Pro
20 25 30
Gln Pro Ser Ala Glu Ala Ala Ala Ala Pro Ser Leu Ala Asn Ile Ser
35 40 45

NEED FIVE FORM TO MAKE A VOL. II FILE

EXPRESS MAIL
UNITED STATES POSTAL SERVICE
Post Office To Addressee

EV 332017306 US

ORIGIN (POSTAL USE ONLY)

PO ZIP Code: 94126
Date In: Mo. 8 Day 14 Year 03
Time In: 17 45
Weight: 1 lbs. 14 ozs.
No Delivery: ☐ Weekend ☐ Holiday
Day of Delivery: ☐ Next ☒ Second ☐ 12 Noon ☒ 3 PM ☐ Military ☐ 2nd Day ☐ 3rd Day
Int'l Alpha Country Code:
Acceptance Clerk Initials:
Flat Rate Envelope ☐
Postage: $ 17.85
Return Receipt Fee:
COD Fee:
Insurance Fee:
Total Postage & Fees: $ 17.85

DELIVERY (POSTAL USE ONLY)

Delivery Attempt: Mo. Day Time ☐ AM ☐ PM Employee Signature
Delivery Attempt: Mo. Day Time ☐ AM ☐ PM Employee Signature
Delivery Date: Mo. Day Time ☐ AM ☐ PM
Delivered

SAN FRANCISCO CA GATEWAY STN AUG 14 2003 USPS

CUSTOMER USE ONLY
METHOD OF PAYMENT: Express Mail Corporate Acct. No: X941886
Federal Agency Acct. No. or Postal Service Acct. No.:

FROM: (PLEASE PRINT) PHONE 415 576-0200
TOWNSEND & TOWNSEND & CREW
2 EMBARCADERO CTR FL 8
SAN FRANCISCO CA 94111-3819
Carol A. Fang/kj1
014058-014402PC
14 August 2003

TO: (PLEASE PRINT) PHONE
MAIL STOP PCT
COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA VA 22313-1450
CHAPTER II DEMAND, ART. 34 AMENDMENTS W/sub pgs; 15 FORMAL DWGS; STATEMENT; SEQ LISTING AND DISKETTE

PRESS HARD. You are making 3 copies.
FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com
www.usps.com

EV332017306US

KSF

PCT20 Rec'd PCT/PTO 14 AUG 2003

TO THE U.S. PATENT & TRADEMARK OFFICE
Please stamp and date receipt of the following document(s) and return this card to us:

Corixa Corporation

RE: CHAPTER II DEMAND

TITLE OF DOCUMENT(S):
Transmittal Letter; Letter to Officer; Chapter II Demand; Article 34 Amendment with ten (10) substitute pages 15, 20, 20a, 22, 161, 167, 167a, 169, 171, and 234; fifteen (15) sheets of Formal Drawings (Figs. 1-8); Statement; Sequence Listing (120 pages), and Diskette

Chp 2 Demand 8-22-03

UNDOCKETED BY CC

Chp 1 nat phase 9-22-03
Furnish Seq Listing 8-22-03

Application No.	PCT/US03/02353
File No.	014058-014402PC
Date Due	22 August 2003
Date Mailed	14 August 2003
Atty/filer	Carol A. Fang/kji
Express Mail Label No.	EV 332 017 306 US

60018169 v1

Please stamp date of receipt of the enclosed documents and return this card to addressee

TRANSMITTAL LETTER TO THE UNITED STATES RECEIVING OFFICE

DATE	August 2003
INTERNATIONAL APPL. NO.	PCT/US03/02353
ATTY DOCKET NO.	14058-14402P

I. Certification under 37 CFR 1.10 (if applicable)

EV 332 017 306 US	14 August 2003
Express Mail mailing number	Date of Deposit

II. ☐ New International Application

Title		Earliest priority date (Day/Month/Year)

SCREENING DISCLOSURE INFORMATION: In order to assist in screening the accompanying international application for purposes of determining whether a license for foreign transmittal should and could be granted and for other purposes, the following information is supplied. (Note: check as many boxes as apply):

A. ☐ The invention disclosed was **not** made in the United States.
B. ☐ There is no prior U.S. application relating to this invention.
C. ☐ The following prior U.S. application(s) contain subject matter which is related to the invention disclosed in the attached international application. (NOTE: *priority to these applications may or may not be claimed on form PCT/RO/101 (Request) and this listing does not constitute a claims for priority).*

application no.		filed on	
application no.		filed on	

D. ☐ The present international application ☐ contains additional subject matter not found in the prior U.S. application(s) identified in paragraph C above. The additional subject matter is found on pages:_____; and ☐ **DOES NOT ALTER** ☐ **MIGHT BE CONSIDERED TO ALTER** the general nature of the invention in a manner which would require the U.S. application to have been made available for inspection by the appropriate defense agencies under 35 USC 181 and 37 CFR 5.1. See 37 CFR 5.15.

III. ☐ A Response to an Invitation from the RO/US. The following document(s) is (are) enclosed:

A. ☐ A Request for an Extension of Time to File a Response.
B. ☐ Power of Attorney (General or Regular)
C. ☐ Replacement pages:

pages		of the request (PCT/RO/101)	pages		of the figures
pages		of the description	pages		of the abstract
pages		of the claims			

D. ☐ Submission of Priority Documents

Priority document		Priority document	

E. ☐ Fees as specified on attached Fee Calculation sheet form PCT/RO/101 annex

IV. ☐ A Request for rectification under PCT 91 ☐ A Petition ☒ Statement, Seq. Listing & Diskette

V. ☒ Other: ☒ Chapter II Demand ☒ Letter ☒ Postcard ☒ Article 34 Amendment w/10 sub pgs. ☒ Fifteen (15) sheets of Formal Drawings (Figs. 1-8)

The Commissioner is hereby authorized to charge any additional fees associated with this paper or during the pendency of this application, or credit any overpayment, to Deposit Account No. 20-1430.

The person signing this form is the		
	☐ Applicant	Carol A. Fang
	☒ Attorney/Agent (Reg. No.) 48,631	Typed name of signer
	☐ Common Representative	
		Signature

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☑ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.